Patient Perspective on Cross-Linking

Learn more about the importance of early diagnosis and treatment from a keratoconus patient and her treating physician.

A General Overview

Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.

Corneal Cross-Linking:
  • Creates new corneal collagen cross-links
  • Results in a shortening and thickening of the collagen fibrils
  • Leads to the stiffening of the cornea

Top Questions to Ask Your Eye Doctor Download PDF

FDA Approval

The first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus.

In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.

The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.

Cross-Linking

Learn more about this outpatient procedure

View our Living with Keratoconus Patient Brochure.

Patient FAQs

Discover answers to the most common questions surrounding cross-linking

Visit the Patient FAQ Section to learn more.

It is estimated that...

1 Out of Every 2,000

persons in the general population have Keratoconus1

You can find more information from the National Keratoconus Foundation.

1. Kennedy R. H., Bourne W. M., Dyer J. A. A 48-year clinical and epidemiologic study of keratoconus. The American Journal of Ophthalmology. 1986;101(3):267–273. doi: 10.1016/0002-9394(86)90817-2.

Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."

Mary Prudden, Executive Director for the National Keratoconus Foundation

What are Patients Saying? View Stories

Learn More Through Our Facebook Page

2 days ago

Living with KC

Looking for a #crosslinking expert near you? Visit our website to find a specialist who is performing the FDA approved procedure: www.livingwithkeratoconus.com/find-an-expert/ #KCExperts ... See MoreSee Less

View on Facebook

2 days ago

Living with KC

Do you play video games and are looking to get an edge on your opponents? This #SaveYourVisionMonth, the American Academy of Ophthalmology Association is encouraging gamers to use the 20-20-20 rule to give their eyes a rest from digital eye strain ow.ly/h2G850n210p ... See MoreSee Less

View on Facebook

3 days ago

Living with KC

At this time, the exact cause of #keratoconus is unknown. In response to this, Fight for Sight announced its support of an investigation into the causes of KC. ow.ly/Q45l50mGCi5 ... See MoreSee Less

View on Facebook

4 days ago

Living with KC

#ICYMI - Dr. Joseph D. Iuorno of Commonwealth Eye Care Associates is on the #LivingWithKC blog discussing FDA approved #crosslinking and insurance. Visit our website to learn more! ow.ly/qltz50mGASC ... See MoreSee Less

View on Facebook

Learn More Through Our Twitter Page

#FactFriday - Dry eye occurs when the #eye does not produce enough tears or when they quality of the tears can't keep the eye adequately lubricated. The @aao_ophth shares a variety of treatment approaches that may help the condition: https://t.co/ei3U6lVkZx

Looking for a #crosslinking expert near you? Visit our website to find a specialist who is performing the FDA approved procedure: https://t.co/lPQNrdMU7w #KCExperts

Do you play video games and are looking to get an edge on your opponents? This #SaveYourVisionMonth, the @AOAConnect is encouraging gamers to use the 20-20-20 rule to give their eyes a rest from digital eye strain https://t.co/vncgitBVwY

At this time, the exact cause of #keratoconus is unknown. In response to this, Fight for Sight announced its support of an investigation into the causes of KC. https://t.co/WzKfSMibDZ

#ICYMI - Dr. Joseph D. Iuorno of @CommonwealthECA is on the #LivingWithKC blog discussing FDA approved #crosslinking and insurance. Visit our website to learn more! https://t.co/vA0eDZjh0J

Load More...

Learn More Through Our Instagram

MA-00687B